Biologics targeted at TNF: design, production and challenges

Abstract Views: 1755
PDF: 2488
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Autoimmune diseases affect millions of people worldwide and, with more than 70 distinct types of pathologies associated with autoimmune processes, represent a wide and fast-moving area of research and clinical interest (1). Extensive preclinical research has focused on the regulation of cytokine expression with special interest in rheumatoid arthritis (RA), and this multidisciplinary effort has contributed to elucidate the roles of cytokines in this and other disabling autoimmune diseases. Tumor necrosis factor alpha (TNFa) emerged from these studies as a pivotal regulator of expression of other pro-inflammatory cytokines such as Interleukin-1 (IL-1) and Interleukin-6 (IL- 6) (2), thus becoming a key target for therapeutic intervention in a redundant cytokine environment...

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Gatto, B. (2006). Biologics targeted at TNF: design, production and challenges. Reumatismo, 58(2), 94–103. https://doi.org/10.4081/reumatismo.2006.94